Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-36143
Titel: Systemic Steroids in Preventing Bronchopulmonary Dysplasia (BPD): Neurodevelopmental Outcome According to the Risk of BPD in the EPICE Cohort
VerfasserIn: Zayat, Noura
Truffert, Patrick
Drumez, Elodie
Duhamel, Alain
Labreuche, Julien
Zemlin, Michael
Milligan, David
Maier, Rolf F.
Jarreau, Pierre-Henri
Torchin, Héloïse
Zeitlin, Jennifer
Nuytten, Alexandra
On behalf of the EPICE Research Group
Sprache: Englisch
Titel: International Journal of Environmental Research and Public Health
Bandnummer: 19
Heft: 9
Verlag/Plattform: MDPI
Erscheinungsjahr: 2022
Freie Schlagwörter: neurodevelopmental outcome
bronchopulmonary dysplasia
preterm birth
post natal steroid therapy
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Background: Postnatal steroids (PNS) have been used to prevent bronchopulmonary dysplasia (BPD) in preterm infants but have potential adverse effects on neurodevelopment. These effects might be modulated by their risk of BPD. We aimed to compare patients’ neurodevelopment with PNS treatment according to their risk of BPD in a European cohort. Methods: We developed a prediction model for BPD to classify infants born between 24 + 0 and 29 + 6 weeks of gestation in three groups and compared patients’ neurological outcome at two years of corrected age using the propensity score (PS) method. Results: Of 3662 neonates included in the analysis, 901 (24.6%) were diagnosed with BPD. Our prediction model for BPD had an area under the ROC curve of 0.82. In the group with the highest risk of developing BPD, PNS were associated with an increased risk of gross motor impairment: OR of 1.95 after IPTW adjustment (95% CI 1.18 to 3.24, p = 0.010). This difference existed regardless of the type of steroid used. However, there was an increased risk of cognitive anomalies for patients treated with dexa/betamethasone that was no longer observed with hydrocortisone. Conclusions: This study suggests that PNS might be associated with an increased risk of gross motor impairment regardless of the group risk for BPD. Further randomised controlled trials exploring the use of PNS to prevent BPD should include a risk-based evaluation of neurodevelopmental outcomes. This observation still needs to be confirmed in a randomised controlled trial.
DOI der Erstveröffentlichung: 10.3390/ijerph19095600
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-361439
hdl:20.500.11880/32951
http://dx.doi.org/10.22028/D291-36143
ISSN: 1660-4601
Datum des Eintrags: 30-Mai-2022
Bezeichnung des in Beziehung stehenden Objekts: Supplementary Materials
In Beziehung stehendes Objekt: https://www.mdpi.com/article/10.3390/ijerph19095600/s1
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Pädiatrie
Professur: M - Prof. Dr. Michael Zemlin
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
ijerph-19-05600.pdf1,3 MBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons